Probes: FGFR2 (10q26.13)
Disease(s): Cholangiocarcinoma (bile duct cancer) and various solid tumors
FGFR2 fusions are under active clinical study in a range of solid tumors, with targeted therapy already available to certain cholangiocarcinoma patients. FGFR2 fusions occur at highest frequency in intrahepatic cholangiocarcinoma (iCCC), observed in 10-16% of patients. This lab-developed test uses a break-apart FISH probe to detect the presence of FGFR2 fusions (translocations). Fusion partners of FGFR2 are not specifically identified.
As a reminder, FGFR2 CDx Molecular Analysis remains the appropriate test for urinary bladder cancer targeted therapy.
Bone marrow aspirate: N/A
Peripheral blood: N/A
Fresh, unfixed tissue: N/A.
Paraffin block: Send paraffin block. Also send circled H&E slide for tech-only (required).
Cut slides: H&E slide (required) plus 4 unstained slides cut at 4-5 microns. Circle H&E slide for tech-only.
Use cold pack for transport. Make sure cold pack is not in direct contact with specimen.
Newsroom page, published April 20, 2020. Am J Managed Care website. https://www.ajmc.com/newsroom/-fda-approves-orphan-drug-pemigatinib-for-rare-bile-duct-cancer-cholangiocarcinoma. Accessed June 20, 2020